The Effect of Andrographolide on Induce Senescence in Human Hepatocellular Carcinoma HepG2 Cells

Purpose: To determine whether andrographolide can induce senescence of human hepatocellular carcinoma HepG2 cells in vivo or in vitro. If so, the mechanism by which andrographolide induces senescence in human hepatocellular carcinoma HepG2 cells will also be explored. Methods: The study will use human hepatocellular carcinoma cell line HepG2. HepG2 will be treated with different doses and different durations of Andrographolide. HepG2 cells were implanted in mice to form artificial hepatocellular carcinoma, and Andrographolide use to treat the artificial hepatocellular carcinoma. Measure senesscence by by b-gal kit, the abundance of p21 and p53 by western blot, viability by tunnel assay. Positive control is MLN4924 and negative control is DMSO/PBS. Possible Results: There are two main possible results: (1) Andrographolide was able to induce senescence in human hepatocellular carcinoma HepG2 cells by increasing p21 and p53 leading to decreased HepG2 viability. (2) Andrographolide had no significant effect on human hepatocellular carcinoma HepG2 cells. Conclusions: In this study, I found that Andrographolide has potential anti-tumour effects against hepatocellular carcinoma. Andrographolide was shown to induce senescence of hepatocellular carcinoma HepG2 cells via p53/p21 in vitro and in vivo. Therefore, Andrographolide is a promising senescence-inducing therapy for the treatment of human hepatocellular carcinoma.